Exact Sciences Corp revenue decreases to $602.45 million in quarter ended Mar 31, 2023 from previous quarter

By NewsInMinutes on May 10, 2023 | 04:30 AM IST

Current Reporting	Revenue	Net Income	Profit/Loss
Mar 2023	$602.45 million	$74.15 million	loss
Sep 2022	$0.5231 million	$0.15 million	loss
Jun 2022	$521.64 million	$166.06 million	loss

Exact Sciences Corp [EXAS] has reported $74.15 million loss for the fiscal quarter ending Mar 31, 2023.

Revenue for the quarter was $602.45 million with operating income of $77.09 million.

The Madison, Wisconsin (WI)-based company operating in the medical laboratories sector has total shareholders equity of $3,057.71 million.

Also read:

Exact Sciences Highlights the Impact of Precision Oncology Portfolio on Breast Cancer Treatment with 10 New Data Presentations at SABCS® 2022

Global In-Vitro Diagnostics (IVD) Market to Swell by 4.6% Annually Through 2031 on the Back of Increasing Healthcare Expenditure - ResearchAndMarkets.com

Liquid Biopsy Global Market Report 2022: Cancer Awareness Initiatives Undertaken by Global Health Organizations Drive Growth - ResearchAndMarkets.com

This is a developing story. Click here to receive updates.

------------

NewsInMinutes, an offering of 10kInfo, Inc., brings you news on the latest regulatory filings. Subscribe to additional news alerts here.

Stock View